Navigation Links
New Study Questions Cannibalism As A Worldwide Selective Force

iants - in the PRNP gene. This data was used to assess the ages of the mutations, to identify geographic patterns of variation, and to evaluate selective forces that have potentially influenced these patterns.

"In contrast to the previous study, which concluded that variation in the PRNP gene was strongly skewed toward intermediate frequency variants, our results showed that there was, in fact, a deficit of intermediate frequency variants," says Bertranpetit. "Our results are consistent with a complex history of episodic or fluctuating selection, including positive selection, purifying selection, and possibly even short periods of balancing selection."

On a more technical note, the study cautions researchers involved in SNP-based population genetics studies. The work is among the first to empirically demonstrate how SNP ascertainment can introduce a strong bias in population genetics studies and seriously distort the conclusions. Bertranpetit and his colleagues point out that at a time when a flood of ascertained SNP data is being generated, it is essential that SNP ascertainment be taken into consideration in data analyses.

The first author on the study is Dr. Marta Soldevila, who completed her Ph.D. at the Universitat Pompeu Fabra and performed a substantial part of the sequencing work at DeCODE Genetics (Reykjavik, Iceland).


'"/>




Page: 1 2

Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
Breaking Medicine Technology:New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4Confusion Over Homeopathic Medicines in Alexa Ray Joel's Hospitalization Clarified by the American Association of Homeopathic Pharmacists (AAHP) 2DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 1DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 2DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 3DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 4DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 5DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 6Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 1Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 2Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 3YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 1YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 2YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 3YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 4
Other Medicine Technology:Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 2Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 3Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 4Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 2Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 3Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 4Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 6